Guardian Pharmacy Services, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
GRDN$49.85+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
| (In thousands, except share amounts) · Class A Shares · Class B Shares · Class A Amount · Class B Amount · Additional Paid-in capital · Retained Earnings · Non-ControllingInterests · Total Equity | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2025 | 36,253,744 | 27,066,890 | $36 | $27 | $139,353 | $66,343 | $12,165 | $217,924 | |||||
| Contributions | — | — | — | — | — | — | 79 | 79 | |||||
| Distributions | — | — | — | — | — | — | (960) | (960) | |||||
| Net income attributable to Guardian Pharmacy Services, Inc. | — | — | — | — | — | 13,295 | — | 13,295 | |||||
| Net income attributable to non-controlling interest | — | — | — | — | — | — | 249 | 249 | |||||
| Share-based compensation forfeitures | — | — | — | — | (47) | — | — | (47) | |||||
| Share-based compensation expense | — | — | — | — | 1,794 | — | — | 1,794 | |||||
| Conversion of Class B common stock to Class A common stock | 13,527,437 | (13,527,437) | 14 | (14) | — | — | — | — | |||||
| Other | — | — | — | — | 90 | — | — | 90 | |||||
| Balance, March 31, 2026 | 49,781,181 | 13,539,453 | $50 | $13 | $141,190 | $79,638 | $11,533 | $232,424 | |||||
| Contributions | — | — | — | — | — | — | 574 | 574 | |||||
| Distributions | — | — | — | — | — | — | (327) | (327) | |||||
| Net income attributable to Guardian Pharmacy Services, Inc. | — | — | — | — | — | 21,872 | — | 21,872 | |||||
| Net income attributable to non-controlling interest | — | — | — | — | — | — | 249 | 249 | |||||
| Share-based compensation forfeitures | — | — | — | — | (48) | — | — | (48) | |||||
| Share-based compensation expense | — | — | — | — | 2,898 | — | — | 2,898 | |||||
| Issuance of Class A common stock associated with vested restricted stock units | 11,703 | — | — | — | — | — | — | — | |||||
| Balance, June 30, 2026 | 49,792,884 | 13,539,453 | $50 | $13 | $144,040 | $101,510 | $12,029 | $257,642 | |||||
| Contributions | — | — | — | — | — | — | 527 | 527 | |||||
| Distributions | — | — | — | — | — | — | (511) | (511) | |||||
| Net income attributable to Guardian Pharmacy Services, Inc. | — | — | — | — | — | 18,680 | — | 18,680 | |||||
| Net income attributable to non-controlling interest | — | — | — | — | — | — | 440 | 440 | |||||
| Share-based compensation forfeitures | — | — | — | — | (279) | — | — | (279) | |||||
| Share-based compensation expense | — | — | — | — | 2,843 | — | — | 2,843 | |||||
| Conversion of Class B common stock to Class A common stock | 13,527,416 | (13,527,416) | 13 | (13) | — | — | — | — | |||||
| Issuance of Class B common stock associated with acquisition | — | 9,967 | — | — | 378 | — | — | 378 | |||||
| Balance, September 30, 2026 | 63,320,300 | 22,004 | $63 | $— | $146,982 | $120,190 | $12,485 | $279,720 | |||||
| (In thousands, except share amounts) · Class A Shares · Class B Shares · Class A Amount · Class B Amount · Additional Paid-in capital · Retained Earnings · Non-ControllingInterests · Total Equity | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2024 | 9,200,000 | 54,087,158 | $9 | $54 | $125,484 | $17,124 | $7,305 | $149,976 | |||||
| Contributions | — | — | — | — | — | — | 135 | 135 | |||||
| Distributions | — | — | — | — | — | — | (135) | (135) | |||||
| Net income attributable to Guardian Pharmacy Services, Inc. | — | — | — | — | — | 9,448 | — | 9,448 | |||||
| Net income (loss) attributable to non-controlling interest | — | — | — | — | — | — | (175) | (175) | |||||
| Share-based compensation forfeitures | — | (516) | — | — | (1) | — | — | (1) | |||||
| Share-based compensation expense | — | — | — | — | 3,969 | — | — | 3,969 | |||||
| Conversion of Class B common stock to Class A common stock | 13,519,946 | (13,519,946) | 14 | (14) | — | — | — | — | |||||
| Balance, March 31, 2025 | 22,719,946 | 40,566,696 | $23 | $40 | $129,452 | $26,572 | $7,130 | $163,217 | |||||
| Contributions | — | — | — | — | — | — | 1,094 | 1,094 | |||||
| Non-cash equity contribution | — | — | — | — | — | — | 2,141 | 2,141 | |||||
| Distributions | — | — | — | — | — | — | (54) | (54) | |||||
| Net income attributable to Guardian Pharmacy Services, Inc. | — | — | — | — | — | 9,030 | — | 9,030 | |||||
| Net income (loss) attributable to non-controlling interest | — | — | — | — | — | — | (203) | (203) | |||||
| Share-based compensation forfeitures | (68) | (202) | — | — | (1) | — | — | (1) | |||||
| Share-based compensation expense | — | — | — | — | 4,447 | — | — | 4,447 | |||||
| Issuance of Class A common stock associated with vested restricted stock units | 10,713 | — | — | — | — | — | — | — | |||||
| Balance, June 30, 2025 | 22,730,591 | 40,566,494 | $23 | $40 | $133,898 | $35,602 | $10,108 | $179,671 | |||||
| Contributions | — | — | — | — | — | — | 390 | 390 | |||||
| Non-cash equity contribution | — | — | — | — | — | — | 1,468 | 1,468 | |||||
| Distributions | — | — | — | — | (422) | — | — | (422) | |||||
| Net income attributable to Guardian Pharmacy Services, Inc. | — | — | — | — | — | 9,818 | — | 9,818 | |||||
| Net income (loss) attributable to non-controlling interest | — | — | — | — | — | — | (225) | (225) | |||||
| Share-based compensation forfeitures | (132) | (394) | — | — | (17) | — | — | (17) | |||||
| Share-based compensation expense | — | — | — | — | 4,373 | — | — | 4,373 | |||||
| Conversion of Class B common stock to Class A common stock | 13,523,285 | (13,523,285) | 13 | (13) | — | — | — | — | |||||
| Issuance of Class B common stock associated with acquisition | — | 24,075 | — | — | 441 | — | — | 441 | |||||
| Balance, September 30, 2025 | 36,253,744 | 27,066,890 | $36 | $27 | $138,273 | $45,420 | $11,741 | $195,497 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.